Denali Therapeutics, Inc. (DNLI)
20.70
-0.98
(-4.52%)
USD |
NASDAQ |
Apr 16, 16:00
20.70
0.00 (0.00%)
After-Hours: 17:18
Denali Therapeutics Research and Development Expense (Quarterly) : 97.90M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Neurocrine Biosciences, Inc. | 258.20M |
| Protalix Biotherapeutics, Inc. | 5.635M |
| Biogen, Inc. | 434.00M |
| Agenus, Inc. | 7.511M |
| Curis, Inc. | 5.825M |